Tagged Articles

Jentadueto 6 articles

New pancreatitis warnings added to diabetes drugs Tradjenta, Jentadueto

The safety labels for the type 2 diabetes drugs Tradjenta (linagliptin tablets) and Jentadueto (linagliptin and metformin) have been updated to include a warning that using the drugs may cause a type of pancreas inflammation known as pancreatitis, which in some cases can be fatal. Tradjenta and Jentadueto, which both include the active ingredient linagliptin, are in a class of oral medications known as dipeptidyl peptidase 4, or DPP-4 inhibitors. Other drugs in this class include Januvia and Onglyza. The warnings state that there have been post-marketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Doctors who ... Read More

Type 2 diabetes drug does not reduce risk of heart attack, stroke, death

Diabetes drug Onglyza (saxagliptin) does not reduce the risk of heart attacks, strokes or death from cardiovascular causes compared to a placebo, drug makers Bristol Myers Squibb and AstraZeneca said. The companies had conducted clinical trials to determine if the Type 2 diabetes treatment could help reduce the risk of non-fatal heart attacks and ischemic strokes and death from cardiovascular problems as well as lower blood glucose levels. Onglyza did not perform better than a placebo; however, it was not inferior to the placebo either. The clinical trials involved 16,500 people with diabetes as well as a history of heart ... Read More

Class of type 2 diabetes drugs linked to acute pancreatitis, pancreatic cancer, thyroid cancer

Concerns over the safety of a class of type 2 diabetes drugs known as incretin mimetics – glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors – took a sharp turn recently after an investigative report by British media revealed that it uncovered unpublished data that links the drugs to “unwanted proliferative or inflammatory pancreatic effects,” and that drug regulators in the United States and Europe have not responded quickly enough to studies that suggest these drugs are not as safe as manufacturers claim. Incretin mimetic drugs include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, ... Read More

Lawsuits filed against makers of several type 2 diabetes drugs

Last month, the Food and Drug Administration (FDA) announced that it was investigating cases of pancreatitis and precancerous cellular changes called pancreatic duct metaplasia in patients taking a class of type 2 diabetes drugs known as incretin mimetics. Lawsuits against manufacturers of several of these drugs have been underway for years. Incretin mimetic drugs include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). The FDA’s inquiry is based on unpublished findings from a group of academic researchers who examined a small number of pancreatic tissue ... Read More

European drug regulators investigate pancreas risks with popular type 2 diabetes drugs

The European Medicines Agency is investigating whether a class of type 2 diabetes medications increases the risk of pancreatitis (inflammation of the pancreas) and precancerous cellular changes called pancreatic-duct metaplasia. The investigation involves so-called GLP-1-based therapies (glucagon-like-peptide-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors. GLP-1 therapies are also known as incretin mimetics and include the drugs exenatide (Byetta, Bydureon), liraglutide (Victoza), lixisenatide (Lyxumia), sitagliptin (Efficib, Januvia, Janumet, Ristaben, Ristfor, Tesavel, Velmetia, Xelevia), saxagliptin (Komboglyze, Onglyza), linagliptin (Jentadueto, Trajenta), and vildagliptin (Eucreas, Galvus, Icandra, Jalra, Xiliarx, Zomarist). The investigation comes just days after the U.S. Food and Drug Administration (FDA) announced it was ... Read More

FDA investigates cases of pancreatitis, precancerous pancreatic cancer with type 2 diabetes treatments

An increased risk of pancreatitis, or inflammation of the pancreas, and other precancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics is being evaluated by the Food and Drug Administration (FDA). The investigation is based on unpublished findings by a group of academic researchers who examined a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. Incretin mimetic drugs include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin ... Read More